AEON Biopharma, Inc. (AEON) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
AEON Biopharma, Inc. (AEON) Earnings Overview
As of June 13, 2026, AEON Biopharma, Inc. (AEON) reported trailing twelve-month net income of -$60M, reflecting -105.4% year-over-year growth. The company earned $-4.97 per diluted share over the past four quarters.
Looking at the long-term picture, AEON's historical earnings data spans multiple years. The company achieved its highest annual net income of $173M in fiscal 2019.
AEON Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REVB (-$10M net income), NUVL (-$450M net income), ACTU (-$22M net income), AEON has comparable earnings metrics. Compare AEON vs REVB →
AEON Earnings vs Peers
Earnings metrics vs comparable public companies
AEON Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | -193.4% | -$13M | $-3.95 | - | - |
| 2024 | $42M | +110.9% | $73M | $72.93 | - | - |
| 2023 | -$385M | -631.9% | -$348M | $-4.99 | - | - |
| 2022 | -$53M | +5.5% | -$48M | $-27.25 | - | - |
| 2021 | -$56M | -69.0% | -$66M | $-31.73 | - | - |
| 2020 | -$33M | -119.0% | -$16M | $-547.60 | -1307.1% | -650.8% |
| 2019 | $173M | - | -$54M | $1481.04 | 5151.0% | -1607.6% |
Download Data
Export AEON earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in AEON back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in AEON be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AEON Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAEON vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowAEON — Frequently Asked Questions
Quick answers to the most common questions about buying AEON stock.
What is AEON earnings per share (EPS)?
AEON trailing twelve-month (TTM) diluted EPS is $-4.97, reflecting -105.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is AEON Biopharma, Inc.'s net income?
AEON Biopharma, Inc. (AEON) trailing twelve-month net income is $-60M as of 2025. Earnings declined -105.4% year-over-year.
Is AEON profitable?
AEON is not currently profitable on a TTM basis, reporting a net loss of $-60M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AEON's earnings growth rate?
AEON compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are AEON's profit margins?
AEON Biopharma, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is AEON growing earnings?
AEON earnings are declining — EPS fell -105.4% year-over-year. TTM net income dropped to $-60M. This contrasts with the 5-year CAGR of N/A.
What was AEON's best earnings year?
AEON Biopharma, Inc.'s highest annual net income on record is $173M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were AEON's earnings last quarter?
AEON's most recent reported quarter was Q1 2026. Net income was $-12M with diluted EPS of $-0.97. For a full breakdown of all quarters, see the quarterly earnings table on this page.